Scott A. Van Wart

1.1k total citations
33 papers, 901 citations indexed

About

Scott A. Van Wart is a scholar working on Pharmacology, Epidemiology and Molecular Medicine. According to data from OpenAlex, Scott A. Van Wart has authored 33 papers receiving a total of 901 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pharmacology, 14 papers in Epidemiology and 9 papers in Molecular Medicine. Recurrent topics in Scott A. Van Wart's work include Antibiotics Pharmacokinetics and Efficacy (20 papers), Pneumonia and Respiratory Infections (11 papers) and Antibiotic Resistance in Bacteria (9 papers). Scott A. Van Wart is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (20 papers), Pneumonia and Respiratory Infections (11 papers) and Antibiotic Resistance in Bacteria (9 papers). Scott A. Van Wart collaborates with scholars based in United States, United Kingdom and Spain. Scott A. Van Wart's co-authors include Paul G. Ambrose, Sujata M. Bhavnani, Alison Meagher, Brenda Cirincione, Daniel K. Reynolds, Christopher M. Rubino, Julie Passarell, Evelyn J. Ellis‐Grosse, David R. Andes and Timothy Babinchak and has published in prestigious journals such as Blood, Antimicrobial Agents and Chemotherapy and Science Translational Medicine.

In The Last Decade

Scott A. Van Wart

33 papers receiving 869 citations

Peers

Scott A. Van Wart
Rupali Jain United States
Pamela R. Tessier United States
Diane M. Cappelletty United States
Ómar Vesga Colombia
J. Prieto Spain
Giammarco Raponi Italy
Patricia N. Holden United States
Sutep Jaruratanasirikul Thailand
Kim Credito United States
Stefania Fallani Italy
Rupali Jain United States
Scott A. Van Wart
Citations per year, relative to Scott A. Van Wart Scott A. Van Wart (= 1×) peers Rupali Jain

Countries citing papers authored by Scott A. Van Wart

Since Specialization
Citations

This map shows the geographic impact of Scott A. Van Wart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott A. Van Wart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott A. Van Wart more than expected).

Fields of papers citing papers by Scott A. Van Wart

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott A. Van Wart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott A. Van Wart. The network helps show where Scott A. Van Wart may publish in the future.

Co-authorship network of co-authors of Scott A. Van Wart

This figure shows the co-authorship network connecting the top 25 collaborators of Scott A. Van Wart. A scholar is included among the top collaborators of Scott A. Van Wart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott A. Van Wart. Scott A. Van Wart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wart, Scott A. Van, et al.. (2025). Population pharmacokinetic analysis of tobramycin in serum and ELF using data from patients with pneumonia. Antimicrobial Agents and Chemotherapy. 69(5). e0090824–e0090824. 1 indexed citations
2.
3.
4.
Lakota, Elizabeth A., Scott A. Van Wart, Evan Tzanis, et al.. (2020). Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data. Antimicrobial Agents and Chemotherapy. 64(7). 19 indexed citations
5.
Seroogy, Julie D., Scott A. Van Wart, Sujata M. Bhavnani, et al.. (2019). Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2, and 3 Clinical Studies. Antimicrobial Agents and Chemotherapy. 63(4). 21 indexed citations
6.
Rhodes, Nathaniel J., et al.. (2017). Defining the impact of severity of illness on time above the MIC threshold for cefepime in Gram-negative bacteraemia: a ‘Goldilocks’ window. International Journal of Antimicrobial Agents. 50(3). 487–490. 19 indexed citations
7.
Bulik, Catharine C., Justin Bader, Li Zhang, et al.. (2017). PK–PD Compass: bringing infectious diseases pharmacometrics to the patient’s bedside. Journal of Pharmacokinetics and Pharmacodynamics. 44(2). 161–177. 11 indexed citations
8.
Schiffer, Joshua T., David A. Swan, Amalia Magaret, et al.. (2016). Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes. Science Translational Medicine. 8(324). 324ra15–324ra15. 27 indexed citations
9.
Wart, Scott A. Van, Alan Forrest, Christopher M. Rubino, et al.. (2013). Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community‐acquired bacterial pneumonia. The Journal of Clinical Pharmacology. 53(11). 1155–1167. 27 indexed citations
10.
Wart, Scott A. Van, Susan E. Shoaf, Suresh Mallikaarjun, & Donald E. Mager. (2013). Population‐based meta‐analysis of hydrochlorothiazide pharmacokinetics. Biopharmaceutics & Drug Disposition. 34(9). 527–539. 19 indexed citations
11.
Kamal, Mohamed, Scott A. Van Wart, Craig R. Rayner, et al.. (2013). Population Pharmacokinetics of Oseltamivir: Pediatrics through Geriatrics. Antimicrobial Agents and Chemotherapy. 57(8). 3470–3477. 20 indexed citations
12.
Wart, Scott A. Van, Susan E. Shoaf, Suresh Mallikaarjun, & Donald E. Mager. (2013). Population‐based meta‐analysis of furosemide pharmacokinetics. Biopharmaceutics & Drug Disposition. 35(2). 119–133. 17 indexed citations
13.
Bhavnani, Sujata M., Jeffrey Hammel, Scott A. Van Wart, et al.. (2013). Pharmacokinetic-Pharmacodynamic Analyses for Efficacy of Ceftaroline Fosamil in Patients with Community-Acquired Bacterial Pneumonia. Antimicrobial Agents and Chemotherapy. 57(12). 6348–6350. 13 indexed citations
14.
Andes, David R., Paul G. Ambrose, Jeffrey Hammel, et al.. (2011). Use of Pharmacokinetic-Pharmacodynamic Analyses To Optimize Therapy with the Systemic Antifungal Micafungin for Invasive Candidiasis or Candidemia. Antimicrobial Agents and Chemotherapy. 55(5). 2113–2121. 83 indexed citations
15.
Ambrose, Paul G., Alison Meagher, Julie Passarell, et al.. (2009). Application of patient population-derived pharmacokinetic–pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci. Diagnostic Microbiology and Infectious Disease. 63(2). 155–159. 17 indexed citations
16.
Wart, Scott A. Van, David R. Andes, Paul G. Ambrose, & Sujata M. Bhavnani. (2009). Pharmacokinetic–pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients. Diagnostic Microbiology and Infectious Disease. 63(4). 409–414. 42 indexed citations
17.
Rubino, Christopher M., Scott A. Van Wart, Sujata M. Bhavnani, et al.. (2009). Oritavancin Population Pharmacokinetics in Healthy Subjects and Patients with Complicated Skin and Skin Structure Infections or Bacteremia. Antimicrobial Agents and Chemotherapy. 53(10). 4422–4428. 69 indexed citations
18.
Ambrose, Paul G., Alison Meagher, Julie Passarell, et al.. (2008). Use of a clinically derived exposure–response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints. Diagnostic Microbiology and Infectious Disease. 63(1). 38–42. 13 indexed citations
19.
Wart, Scott A. Van, et al.. (2007). Population Pharmacokinetics of Tigecycline in Healthy Volunteers. The Journal of Clinical Pharmacology. 47(6). 727–737. 26 indexed citations
20.
Passarell, Julie, Alison Meagher, Brenda Cirincione, et al.. (2007). Exposure-Response Analyses of Tigecycline Efficacy in Patients with Complicated Intra-Abdominal Infections. Antimicrobial Agents and Chemotherapy. 52(1). 204–210. 84 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rupali Jain Breakdown of academic impact, for papers by Pamela R. Tessier Breakdown of academic impact, for papers by Diane M. Cappelletty Breakdown of academic impact, for papers by Ómar Vesga Breakdown of academic impact, for papers by J. Prieto Breakdown of academic impact, for papers by Giammarco Raponi Breakdown of academic impact, for papers by Patricia N. Holden Breakdown of academic impact, for papers by Sutep Jaruratanasirikul Breakdown of academic impact, for papers by Kim Credito Breakdown of academic impact, for papers by Stefania Fallani
Rankless by CCL
2026